A number of transplant organizations from around the world have partnered to develop this educational webinar for the organ donation and transplantation communities. Our goal is to share experiences to date and respond to your questions about the impact of COVID-19 on organ donation and transplantation.
Registration for this free webinar is limited to 1,000 participants. Organizations are asked to consider limiting participation in the live webinar to allow for broad attendance across the donation and transplant community. A recording will be made available for viewing after the call is completed on the AST’s YouTube channel and the UNOS website.
Q&A: Registrants will have the opportunity to submit their individual questions. The moderators and speakers will work to address as many of these questions as possible during the course of the webinar. No live Q&A will be offered during this call.
Up-to-Date Information: The meeting organizers are committed to refreshing this resource and any handouts referenced in the call as new information is learned regarding this virus and its impact on organ donation and transplantation.
Próximos eventos relacionados
2020-11-23 - 2020-11-27 Todo el día
XXII Curso de formación en cirugía hepatobiliopancreática y trasplantes para médicos residentes de 4º y 5º año de la AEC.
2021-01-28 13:00 - 2021-01-30 13:00
Non-hepatic Cancer and Liver Transplantation:
Shifting the Paradigm. Dropping the Cancer Stigma
Time and Date:
January 28, 2021 | starts at 13:00 CET
January 29, 2021 | starts at 13:00 CET
January 30, 2021 | starts at 13:00 CET
Time zone: CET (Central European Time)
Check corresponding international time zones here.
About the Conference
This conference will focus on non-hepatic cancer in the liver transplant setting. Post-transplant malignancy has become a significant cause of mortality. In addition, an increasing number of patients with a history of pre-existing non-hepatic malignancies are being considered for liver transplantation. Careful selection of those with the lowest risk of recurrence, tailored screening, and management with new oncological therapies should be developed and will be discussed by a multidisciplinary set of experts from all over the world.